1. A computer-readable medium having computer-readable components for processing source data, comprising:
an input string display component operable to obtain and display a source string, wherein the source string is associated with metadata, and wherein the metadata includes one or more constraints, and wherein the one or more constraints correspond to evaluation criteria and one or more anchor points operable to project the constraints against the source string.
2. The computer-readable medium as recited in claim 1, wherein the computer-readable medium further comprises:
a comment display component operable to obtain and display comments associated with a source string.
3. The computer-readable medium as recited in claim 1, wherein the computer-readable medium further comprises:
a compiler component operable to infer metadata from the source string, and wherein the inferred metadata is displayed.
4. The computer-readable medium as recited in claim 1, wherein at least one constraint is operable to perform a terminology check, and wherein the result of the terminology check is displayed as a suggestion.
5. The computer-readable medium as recited in claim 1, wherein the computer-readable medium further comprises:
a marking component operable to mark strings displayed to a user according to associated metadata, and wherein the marking component is further operable to identify invalid portions of a string.
6. The computer-readable medium as recited in claim 1, wherein a pseudo-translation of the source string is generated using fuzzying techniques, and wherein the translation is corrected according to associated metadata; and
the computer-readable medium further comprising a translation display component operable to display the pseudo-translation.
7. The computer-readable medium as recited in claim 1, wherein the computer-readable medium further comprises:
a confidence-level component operable to provide an indicator of how difficult a corresponding string will be to translate.
8. The computer-readable medium as recited in claim 1, wherein the computer-readable medium further comprises:
a suggested display component operable to display suggested values of portions of the source string according to the constraints.
9. In a computer system including a display, a method for displaying data, the method comprising:
obtaining source data, wherein the source data includes a source string;
marking the source string according to metadata associated with the source string, wherein the metadata includes one or more constraints, and wherein the one or more constraints correspond to evaluation criteria and one or more anchor points operable to project the constraints against the source string;
displaying the marked source string on the display;
generating a translation of the marked source string; and
displaying the translation on the display.
10. The method as recited in claim 9, wherein the method further comprises:
obtaining suggested values corresponding to at least a portion of the marked source string; and
displaying the suggested values on the display as one or more auto-completes, wherein a user can select one or more of the auto-completes.
11. The method as recited in claim 9, wherein the source string is displayed in a format that corresponds to a resource, and wherein a user can edit the source string in that format.
12. The method as recited in claim 9, wherein the method further comprises:
displaying the associated metadata; and
marking unsatisfied constraints.
13. The method as recited in claim 10, wherein suggested values correspond to modifications of a string such that the modified string validates against the metadata.
14. A method for displaying data comprising:
obtaining source data, wherein the source data includes a source string, and wherein the source string corresponds to metadata, and wherein the metadata includes one or more constraints, and wherein the one or more constraints correspond to evaluation criteria and one or more anchor points operable to place the constraints against the source string;
marking the source string according to the corresponding metadata;
displaying the marked source string on a display;
obtaining a target string, wherein the target string corresponds to a translation of the source string;
marking the target string according to the metadata;
displaying the marked target string on the display; and
displaying information corresponding to projected metadata.
15. The method as recited in claim 14, wherein the information corresponding to projected metadata includes the position of constraints on the source and target strings.
16. The method as recited in claim 14, wherein the information corresponding to projected metadata includes one or more messages alerting a user to unsatisfied constraints.
17. The method as recited in claim 14, wherein the information corresponding to projected metadata includes the position of unsatisfied constraints on the source and target string.
18. The method as recited in claim 14, wherein the method further comprises:
marking invalid string sections.
19. The method as recited in claim 14, wherein the method further comprises:
displaying information corresponding to one or more terms in a string, and wherein the information includes one or more translations which correspond to the one or more terms in the string.
20. The method as recited in claim 14, wherein the method further comprises:
displaying information corresponding to the position of constraints that have been projected onto a string.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I
wherein
X is N or C\u2014R1;
Y is N or C\u2014R2;
Z is N;
R4 is a 6-membered aromatic substituent containing 0, 1 or 2 nitrogen atoms, optionally substituted by 1 to 3 groups, selected from halogen, lower alkyl, lower alkoxy and NRR\u2032;
R1 is lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, lower cycloalkyl or heterocycloalkyl optionally substituted with hydroxy or alkoxy;
R2 is hydrogen, CN, lower alkyl or heterocycloalkyl; and
R and R\u2032 are each independently hydrogen or lower alkyl;
or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, an enantiomers, optical isomer or stereoisomer thereof.
2. The compound of claim 1 having formula IA,
wherein
R4 is a 6-membered aromatic substituent containing 0, 1 or 2 nitrogen atoms, optionally substituted by 1 to 3 groups, selected from halogen, lower alkyl, lower alkoxy and NRR\u2032;
R1 is lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, lower cycloalkyl or heterocycloalkyl optionally substituted with hydroxy or alkoxy;
R2 is hydrogen, CN, lower alkyl or heterocycloalkyl; and
R and R\u2032 are each independently hydrogen or lower alkyl;
or a pharmaceutically acceptable acid addition salt, a racemic mixture, an enantiomers, optical isomer or stereoisomer thereof.
3. The compound of claim 2, selected from the group consisting of
2-Methyl-6-phenylethynyl-pyrazolo1,5-apyrimidine;
6-(2-Fluoro-phenylethynyl)-2-methyl-pyrazolo1,5-apyrimidine;
6-(3-Fluoro-phenylethynyl)-2-methyl-pyrazolo1,5-apyrimidine;
6-(4-Fluoro-phenylethynyl)-2-methyl-pyrazolo1,5-apyrimidine;
2-Methyl-6-pyridin-4-ylethynyl-pyrazolo1,5-apyrimidine;
2-Methyl-6-p-tolylethynyl-pyrazolo1,5-apyrimidine;
6-(4-Chloro-phenylethynyl)-2-methyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-phenylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(2-fluoro-phenylethynyl)-pyrazolo1,5-apyrimidine; and
2-tert-Butyl-6-(3-fluoro-phenylethynyl)-pyrazolo1,5-apyrimidine.
4. The compound of claim 2, selected from the group consisting of
2-tert-Butyl-6-(4-fluoro-phenylethynyl)-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-pyridin-3-ylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-pyridin-4-ylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(4-methoxy-phenylethynyl)-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-m-tolylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(3-methoxy-phenylethynyl)-pyrazolo1,5-apyrimidine;
2-Cyclobutyl-6-phenylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-p-tolylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(4-chloro-phenylethynyl)-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(6-chloro-pyridin-3-ylethynyl)-pyrazolo1,5-apyrimidine; and
5-(2-tert-Butyl-pyrazolo1,5-apyrimidin-6-ylethynyl)-pyridin-2-ylamine.
5. The compound of claim 2, selected from the group consisting of
2-tert-Butyl-6-(5-chloro-pyridin-3-ylethynyl)-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-pyrimidin-5-ylethynyl-pyrazolo1,5-apyrimidine;
2-tert-Butyl-6-(3,4-difluoro-phenylethynyl)-pyrazolo1,5-apyrimidine;
6-Phenylethynyl-2-(tetrahydro-pyran-4-yl)-pyrazolo1,5-apyrimidine;
4-(2-tert-Butyl-pyrazolo1,5-apyrimidin-6-ylethynyl)-phenylamine;
2-(6-Phenylethynyl-pyrazolo1,5-apyrimidin-2-yl)-propan-2-ol;
2-tert-Butyl-6-(5-fluoro-pyridin-3-ylethynyl)-pyrazolo1,5-apyrimidine;
6-Phenylethynyl-pyrazolo1,5-apyrimidine-3-carbonitrile;
3-(2-tert-Butyl-pyrazolo1,5-apyrimidin-6-ylethynyl)-phenylamine;
2-(2-tert-Butyl-pyrazolo1,5-apyrimidin-6-ylethynyl)-phenylamine;
2-tert-Butyl-6-(2,5-difluoro-phenylethynyl)-pyrazolo1,5-apyrimidine; and
2-Isopropyl-6-phenylethynyl-pyrazolo1,5-apyrimidine.
6. The compound of claim 1, having formula IC,
wherein
R4 is a 6-membered aromatic substituent containing 0, 1 or 2 nitrogen atoms, optionally substituted by 1 to 3 groups, selected from halogen, lower alkyl, lower alkoxy and NRR\u2032;
R1 is lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, lower cycloalkyl or heterocycloalkyl optionally substituted with hydroxy or alkoxy; and
R and R\u2032 are each independently hydrogen or lower alkyl;
or a pharmaceutically acceptable acid addition salt, a racemic mixture, an enantiomers, optical isomer or stereoisomer thereof.
7. The compound of claim 6, selected from the group consisting of
2-tert-Butyl-6-phenylethynyl-1,2,4triazolo1,5-apyrimidine;
2-tert-Butyl-6-(2,5-difluoro-phenylethynyl)-1,2,4triazolo1,5-apyrimidine;
2-tert-Butyl-6-(3-fluoro-phenylethynyl)-1,2,4triazolo1,5-apyrimidine;
2-tert-Butyl-6-(3,4-difluoro-phenylethynyl)-1,2,4triazolo1,5-apyrimidine;
2-tert-Butyl-6-(5-chloro-pyridin-3-ylethynyl)-1,2,4triazolo1,5-apyrimidine;
2-Morpholin-4-yl-6-phenylethynyl-1,2,4triazolo1,5-apyrimidine;
2-Morpholin-4-yl-6-m-tolylethynyl-1,2,4triazolo1,5-apyrimidine;
6-(3-Fluoro-phenylethynyl)-2-morpholin-4-yl-1,2,4triazolo1,5-apyrimidine;
6-(3-Chloro-phenylethynyl)-2-morpholin-4-yl-1,2,4triazolo1,5-apyrimidine; and
6-Phenylethynyl-2-pyrrolidin-1-yl-1,2,4triazolo1,5-apyrimidine.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
X is N or C\u2014R1;
Y is N or C\u2014R2;
Z is N;
R4 is a 6-membered aromatic substituent containing 0, 1 or 2 nitrogen atoms, optionally substituted by 1 to 3 groups, selected from halogen, lower alkyl, lower alkoxy and NRR\u2032;
R1 is lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, lower cycloalkyl or heterocycloalkyl optionally substituted with hydroxy or alkoxy;
R2 is hydrogen, CN, lower alkyl or heterocycloalkyl; or
R and R\u2032 are each independently hydrogen or lower alkyl;
or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, an enantiomers, optical isomer or stereoisomer thereof and a pharmaceutically acceptable carrier.